BIOMAT Database Logo BIOMAT Database Logo

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. 1995

J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
Medicine Branch, National Cancer Institute, Bethesda, MD 20852, USA.

In a phase I/II trial assessing the toxicity, pharmacokinetics, and activity of the (-)enantiomer of 2'-deoxy-3'-thiacytidine (3TC, lamivudine), 97 patients with AIDS or advanced human immunodeficiency virus (HIV) disease were administered 3TC at 0.5-20.0 mg/kg/day. The cohort's median entry CD4 cell count was 128/mm3 (range, 7-357). A toxic dose was not reached, although some patients reported mild headache, insomnia, and abdominal symptoms, and there was a general downward trend in neutrophil counts at the highest doses. Although subjective and difficult to interpret, increases in energy and appetite were noted, particularly in patients receiving > or = 8.0 mg/kg/day. Immunologic and virologic parameters showed evidence of at least transient anti-HIV activity at those higher doses. Although further studies of 3TC as monotherapy are needed, its favorable toxicity profile, evidence of at least transient clinical activity, and results of in vitro resistance experiments support further clinical testing in combination therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001613 beta 2-Microglobulin An 11-kDa protein associated with the outer membrane of many cells including LYMPHOCYTES. It is the small subunit of MHC CLASS I MOLECULES. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, CEREBROSPINAL FLUID, and urine of healthy individuals, and to a much greater degree in the urine and plasma of patients with tubular PROTEINURIA, renal failure, or kidney transplants. Thymotaxin,beta 2 Microglobulin
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170

Related Publications

J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
July 1996, The Journal of infectious diseases,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
January 1992, Annals of internal medicine,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.
November 1998, Antimicrobial agents and chemotherapy,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
May 1995, The Journal of infectious diseases,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.
January 1992, Antimicrobial agents and chemotherapy,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
High-performance liquid chromatographic assay for the determination of 2'-deoxy-3'-thiacytidine (lamivudine) in human plasma.
September 2001, Journal of chromatography. B, Biomedical sciences and applications,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
April 1992, Antimicrobial agents and chemotherapy,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.
May 1995, The Journal of infectious diseases,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.
March 1998, Pediatrics,
J M Pluda, and T P Cooley, and J S Montaner, and L E Shay, and N E Reinhalter, and S N Warthan, and J Ruedy, and H M Hirst, and C A Vicary, and J B Quinn
A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.
May 1994, The Journal of infectious diseases,
Copied contents to your clipboard!